Review Article

Percutaneous Ventricular Assist Devices: New Deus Ex Machina?

Diego Arroyo and Stéphane Cook

Cardiology Unit, University Medical Center, University of Fribourg, 1708 Fribourg, Switzerland

Correspondence should be addressed to Stéphane Cook, stephanecook@mac.com

Received 5 October 2010; Revised 22 May 2011; Accepted 25 May 2011

Academic Editor: Casey M. Calkins

Copyright © 2011 D. Arroyo and S. Cook. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The development of ventricular assist devices has broadened the means with which one can treat acute heart failure. Percutaneous ventricular assist devices (pVAD) have risen from recent technological advances. They are smaller, easier, and faster to implant, all important qualities in the setting of acute heart failure. The present paper briefly describes the functioning and assets of the most common devices used today. It gives an overview of the current evidence and indications for left ventricular assist device use in cardiogenic shock and high-risk percutaneous coronary intervention. Finally, extracorporeal life support devices are dealt with in the setting of hemodynamic support.

1. Introduction

Severe heart failure whether acute or chronic is a strenuous clinical challenge. Noninvasive management through inotropic support allows frequent clinical improvement, yet one is repeatedly confronted with refractory cases necessitating more invasive support.

The idea of a mechanical assistance first appeared in the 1950s, yet the first device which is the intra-aortic balloon pump (IABP) only appeared in the late 1960s. It remains, today, the most common, cheapest, and easily available cardiac mechanical device. The most frequent use of IABP is cardiogenic shock with data accounting for 20% of all insertions [1]. It is effective in the stabilization of patients, but it does not provide full cardiac support, and improvement of outcome has not been demonstrated [2]. Hemodynamically, it achieves a maximum of increase of cardiac output of 0.5 L/min. Moreover, its reliance is dependant by the intrinsic cardiac function as well as stable rhythm. In light of these facts, growing interest and expertise have been invested in the development of devices thought to supplement the failing heart. Today, a large pallet of ventricular assist devices is used for a wide range of indications; from long-term replacement of failing hearts to bridge-to-transplantation but also, and foremost, in the temporary support of cardiogenic shock (bridge-to-recovery) and its prophylactic use in certain invasive coronary or valvular procedures.

One differentiates between long- and short-term as well as surgically implanted versus minimally invasive percutaneous ventricular assist devices (pVAD). The latter have the advantage of availability, simplicity of use, and installation. The present review will concentrate on the two pVADs that have received FDA and CE approval for clinical use, the TandemHeart (Cardiac Assist Inc., Pittsburgh, PA, USA) [3] and the Impella Recover LP 2.5 (AbioMed, Europe, Aachen, Germany) [4] (Figure 1). It also includes a section on the use of extracorporeal life support in cardiogenic shock.

2. Device Specificities, Implantation, and Complications

The TandemHeart creates a percutaneous left atrial-to-aortal shunt. Within no more than half an hour, blood is collected from the left atrium, directed to an extracorporeal pump, and then redirected to the abdominal aorta. An operator well trained in transseptal puncture should perform TandemHeart implantation. After gaining femoral venous access, transseptal puncture is performed using standard
Figure 1: Schematic representation of two commercially available percutaneous ventricular assist devices (VAD). (a) The TandemHeart pVAD consists of a 21-F left atrial inflow cannula, an extracorporeal centrifugal pump rotating at up to 7500 rpm, a femoral outflow cannula (15 F–17 F) that extends into the iliac artery, and a microprocessor-based pump controller, which can provide blood flow up to 4 L/min. The tip of the atrial drainage cannula is positioned under fluoroscopic guidance into the left atrium following transseptal puncture. (b) The Impella LP 2.5 is a catheter-mounted device. The microaxial pump consists of an impeller driven by an integrated microelectric motor on the distal end of a flexible catheter. At a maximum speed of 33,000 rpm, the pump provides a maximum hydraulic capacity of 2.5 L/min. The Impella Recover LP 2.5 is retrogradely placed across the aortic valve into the left ventricle where it aspirates blood via a caged blood flow inlet which is then ejected into the ascending aorta.

Brockenbrough technique. When undertaken under cardiopulmonary resuscitation, external cardiac massage should be briefly stopped during a few seconds in order to allow the operator to perform atrial septum puncture. Then, the interatrial septum is dilated using a two-stage (14–21 French) dilator to accommodate the 21-French (Fr) left atrial drainage cannula. Using the Seldinger technique, a 15–17-Fr femoral artery cannula is placed retrogradely in the iliac artery. Both cannulae are connected to the centrifugal pump under careful evacuation of any air within the tubing. The centrifuge is powered by a microprocessor-controlled electromechanical unit, which enables rotation at 3,500 to 7,500 rotations per minute (rpm). The 15-Fr cannula allows a maximal estimated flow of 3.5 L/min and the 17-Fr 4 to 5 L/min depending on systemic vascular resistance. The pump’s efficacy also depends on the proper suction of blood from the left atrium, which could be impaired by wedging of the cannula against the atrial wall in case of deep position of the cannula or inappropriate filling of the left atrium. Special care must be taken to avoid displacement or kinking of the inflow cannula, particularly the dislodgement of the cannula from the left into the right atrium. The latter will result in loss of oxygenation and functionally corresponds to a right-to-left shunt. Therefore, the inflow cannula needs to be secured and immobilized in order to minimize the risk of dislodgement.

Duration of support classically extends from hours to 15 days. When appropriate, a stepwise weaning process (for instance by 500 mL/minute every hour) should be initiated. Weaning criteria are usually met when cardiac index and mean arterial pressure exceed 2.0 L/min/m² and 70 mmHg, respectively, in the absence of end-organ hypoperfusion and without inotropic support. Hemostasis is achieved by manual compression but owing to the large cannula, surgical closure is frequently needed. In comparison, a rather frequent complication (18% of patient with cardiogenic shock at our institution) using the TandemHeart is arterial occlusion and subsequent limb ischemia [5]. Owing to the transseptal puncture, atrial septal defect may persist. Aortic puncture is extremely rare and pericardial tamponade seldom occurs. Finally, particular caution should be made in patients with significant right ventricular failure. Implantation of left-sided TandemHeart might precipitate hemodynamic collapse and death.

The Impella Recover left percutaneous LP 2.5 L/min is a 12-Fr axial flow pump that works on the principle of an Archimedes screw. The impeller is inserted retrogradely through the femoral artery via a 13-Fr peel-away sheath. A 5-Fr Judkins is used to pass through the aortic valve into the left ventricle. The 12 Fr device is then inserted to draw blood out of the left ventricle into the ascending aorta. At maximum speed of 50,000 rpm the pump provides an output of 2.5 L/min. Nine intensities can be adjusted, allowing subtle support. At minimum speed, the pump compensates the aortic regurgitation induced by the catheter. Hemostasis is made by manual compression. The support
is weaker than with TandemHeart and usually of shorter duration (from hours up to five days at our institution). However, implantation due to single arterial puncture and familiar technique is faster than TandemHeart. Another is advantage is the absence of transseptal puncture as well as extracorporeal blood flow. Arterial occlusion is infrequent but haemolysis complicated up to 1/5 of patients and typically occurs within the first 48 hours after support begins.

A similar version, the Impella LP 5.0, achieves a 5 L/min output. The latter requires a surgical procedure [6, 7].

Prior to implantation of either device, angiography of the aorta, iliac, and femoral vessels is mandatory in order to evaluate vessel diameter, presence of obstruction, or disproportionate tortuosity (Figure 2). Both pVADs require anticoagulation with heparin at therapeutic levels with recommended activated clotting time of 250 sec during the procedure and 200 sec during support phase.

Ventricular arrhythmia may complicate the implantation of Impella owing to its intraventricular positioning. A complication common to both pVADs is thrombocytopaenia. Myocardial infarct, atrial cannulation, severe ventricular dysfunction, and postprocedural haemorrhage all contribute to a thromboembolic risk. Infections are usually seen in long-term cardiac assist devices rather than pVADs [8].

Relative contraindications to both pVADs are severe aortic regurgitation, prosthetic aortic valve, as well as aortic aneurysm or dissection. Severe peripheral vascular disease, left ventricular and/or atrial thrombi, severe coagulation disorders, and uncontrolled sepsis further preclude their use.

3. Indications

Cardiogenic shock and high-risk percutaneous coronary intervention (PCI) are two possible indications for percutaneous left ventricular assist devices (Figure 3).

3.1. Cardiogenic Shock (CS). Classically, it is defined on the basis of hemodynamic parameters including systolic systemic blood pressure (sSBP) <90 mmHg for more than 30 min, cardiac index (CI) of <2.2 L/min/m², pulmonary capillary wedge pressure (PCwP) >15 mmHg, and in patients with hypertension a reduction in usual sSBP of >30 mmHg [9]. More importantly it is when cardiac output is severely diminished and responsible for end-organ dysfunction. This enhances neurohumoral responses and systemic inflammatory response syndrome (SIRS) further aggravating the cardiac dysfunction. The incidence of CS in ST-elevated myocardial infarct is unchanged at around 7% [10] and mortality is frighteningly high at 60% despite advances in pharmacological treatment and reperfusion therapy [11].

The benefit expected from the implantation of pVADs is alleviation of the strained cardiac muscle and immediate restoration of cardiac output with physiological organ perfusion, thus breaking the vicious cycle of harmful neurohumoral responses and cytokine production. Evaluating the efficiency in terms of evidence-based medicine is problematic considering the small number of patients who benefit from such therapy. However, patient-based, pVAD implantation is undoubtedly life saving and numerous case reports show successful outcomes [12–14].

Regarding hemodynamic parameters, evidence shows increased cardiac outputs between 37 to 43% with both pVADs as well as a 38% decrease in PCwP [15, 16]. Clinically, the earlier the assistance is initiated the better the outcome with mortality of 26% when pVADs are initiated in the first 2 weeks as opposed to 40% after 2 weeks [17]. Not surprisingly, outcome is worst in case of biventricular failure with weaning from pVADs decreasing from 73% in left ventricular failure to 53% in biventricular failure [18].

Both TandemHeart and Impella Recover LP 2.5 have been compared to IABP. Two randomised trials have evaluated the TandemHeart in comparison to IABP in patients with CS primarily due to acute myocardial infarction [15, 19]. In both, pVAD improved cardiac index and reduced pulmonary capillary wedge pressure significantly. Importantly there was no difference in mortality and the trials were not designed or powered to assess survival differences. Complications such as limb ischemia and severe haemorrhage were more frequent in the pVAD group than the IABP group. One randomised trial compared the Impella Recover LP 2.5 to IABP [20]. Again, cardiac output was significantly improved in the first group, and there were no differences with respect to 30-day mortality.

Kar et al. have recently demonstrated the use of TandemHeart in severe refractory cardiogenic shock of both ischemic and nonischemic origin [21]. In this observational study, 117 patients under IABP and/or high-dose vasopressors were implanted with a TandemHeart, 56 of which underwent active cardiopulmonary resuscitation. Mortality rate at 30 days was 40.2% and 45.3% at 6 months. These are significantly lower than the ranges accounted for in previous...
4 Minimally Invasive Surgery

High-risk PCI → Cardiogenic shock → Cardiopulmonary arrest

Inotropic support + IABP → Deterioration

pVADs/ECLS → sVADs → Transplantation

Figure 3: Schematic clinical uses of percutaneous ventricular assist devices (VAD). PCI: percutaneous coronary intervention, ACLS: acute cardiac life support, IABP: intra-aortic balloon pump, pVAD: percutaneous ventricular assist device, sVAD: surgical ventricular assist device, ECLS: extracorporeal life support. Utility of pVADs stretches from prophylactic use in high-risk PCI to immediate life-saving implantation during cardiopulmonary arrest. In cardiogenic shock especially after myocardial infarction, clinical assessment is necessary and current guidelines favour inotropic support with IABP counterpulsation. pVAD or ECLS implantation completes the management when then patient deteriorates. In case of further decline one should think of sVAD as well as heart transplantation.

trials such as the Shock Trial registry. As in previous trials, complications were frequent, amongst which haemorrhage and limb ischemia.

The Euroshock registry has evaluated the use of Impella Recover 2.5 in 120 patients with cardiogenic shock after acute myocardial infarction [22]. Overall 30-day mortality was 64.2%. The initial hemodynamic profile of patients was poor when compared to other studies reflecting the last-resort use of pVAD. Age over 65 and plasma lactate at admission >3.8 mmol/L were demonstrated to be significant predictors of 30-day mortality. Major cardiac and cerebral events were reported in 15% of patients.

Although encouraging, these data preclude the use of pVADs as first-line mechanical therapy in cardiogenic shock [23].

3.2. Bridging. Significant evidence shows pVAD utility in the bridge-to-recovery concept [24, 25]. This being when the assistance device supports the failing heart in potentially reversible causes of shock such as myocarditis, drug overdose, hypothermia, coronaryography-related complications (air embolism, no-reflow phenomenon, and dissections), incessant arrhythmia, or postcardiotomy syndrome. Similarly, pVADs are reliable and used until more definitive measures can be undertaken such as long-term surgical device implantation (bridge-to-bridge) and transplantation (bridge-to-transplantation) [26, 27].

3.3. High-Risk Percutaneous Coronary and Valvular Interventions. Patients with complex coronary artery disease or unprotected left-main coronary artery as well as severe left main coronary stenosis occasionally present with hemodynamic instability or suffer from such comorbidities that they are considered ineligible for coronary artery bypass graft (CABG). Correspondingly, they are at increased risk for hemodynamic collapse during PCI. Preemptive IABP counterpulsation implantation and even cardiopulmonary bypass have been used to anticipate cardiopulmonary collapse management. Recently, investigators have implanted pVADs with the idea of a better supplementation owing to increased cardiac output. Other pathologies necessitating support are critical aortic stenosis and severe cardiomyopathy.

The first study to have addressed this question showed no significant unloading of the left ventricle [55]. Recently, hemodynamic studies of 11 patients undergoing high-risk PCI with pre-emptive Impella insertion have shown promising results. There was significant left-ventricular unloading as well as decreases in end-diastolic wall stress and improvement in diastolic compliance [65].

So far, there is no randomised control trial, but many observational, retrospective studies show safety of use, little device complications, and lower than predicted mortality at 30 days [56, 66, 67]. Table 1 summarizes the in-hospital survival of patients having undergone high-risk PCI with

| Device | N of patients | 30-day survival |
|--------|--------------|-----------------|
| A. (Cardiogenic shock) | sVAD<sup>a</sup> | 157 | 92 (59%) |
| | pVAD<sup>b</sup> | 102 | 65 (64%) |
| B. (High-risk PCI) | pVAD TH<sup>c</sup> | 113 | 94 (83%) |
| | pVAD IP<sup>d</sup> | 152 | 59 (78%) |

TH means TandemHeart, IP is for Impella Recover 2.5LP; (a) pooled data from 11 trials [17, 28–37], (b) pooled data from 11 trials [5–7, 15, 19, 38–43], (c) pooled data from 11 trials [44–54], and (d) pooled data from 10 trials [55–64].
3-day support with an adapted TandemHeart (pRV AD). Another case report shows successful case report demonstrated the feasibility of pRV AD with been developed for the right ventricle (pRV AD). One initial setting as they aggravate the fragile hemodynamic equilibrium. However, dedicated TandemHeart cannulae have pV AD such as TandemHeart are contraindicated in this management other than rapid reperfusion consists of volume nevertheless emphasise the life-saving potential of pVADs.

5. Extracorporeal Life Support

Extracorporeal life support encompasses life support devices including oxygenation, carbon dioxide removal, and hemodynamic support. It is a form of cardiopulmonary bypass allowing either lung, or both lung and heart support. The basic circuit consists of a venous cannula harvesting deoxygenated blood, a 4000 rpm centrifugal pump with up to 7 L/min high flow, a membrane oxygenator, a heat exchanger, and a returning cannula with oxygenated blood. Two distinct configurations exist, one being a venovenous (VV) cannulation bypassing the lungs and allowing support in respiratory failure. The other being the venoarterial (VA) cannulation where the oxygenated blood is pumped back to the arterial system bypassing lungs and heart providing not only respiratory but also hemodynamic support (see Figure 4). Only the veno-arterial cannulation within the spectrum of hemodynamic support will be considered here.

Technically, the extracting, 22–30-Fr venous cannula is inserted using the Seldinger technique in the right common femoral vein. The 15–23-Fr arterial cannula is placed in the right common femoral artery and maintained in the iliac artery. A supplementary arterial cannula may be inserted distal to the femoral artery cannula to prevent lower limb ischemia. If the lower limb vessels are unsuitable, right common carotid artery or axillary artery cannulation is possible.

Anticoagulation is achieved through continuous unfractionated heparin infusion with recommended ACT between 210 and 230 seconds. Platelet count should be maintained greater than 100,000/microL as shear forces and exposure to foreign body continuously consume them. The duration of support is classically described from 15 to 21 days for femoral access and up to two months for central thoracic access. Complications include local hemorrhage, thromboembolism, lower limb ischaemia, ischemic and hemorrhagic stroke, haemolysis, and infections.

Special attention must be made when cardiac function recovers with flow competing against the ECLS returning blood in the aorta. In case of persistent respiratory failure, the Harlequin syndrome classically describes a blue-headed (deoxygenated blood directed to the upper body) and red-legged patient (hyperoxygenated blood to the lower body). Switch from VA to VV ECLS may then be needed.
Figure 4: Example of extracorporeal life support (ECLS). CARDIOHELP System (MAQUET, Cardiopulmonary AG, Germany). Minimised hand-held ECLS with representation of a femorofemoral, venaarterial cannulation. Deoxygenated blood is harvested in the femoral vein and pumped back to the iliac artery after having passed through the oxygenating membrane and the heat exchanger.

Indications range from severe refractory cardiogenic shock [77], cardiac arrest [78] to failure to wean from cardiopulmonary bypass in cardiac surgery [79] and finally as a bridge [80] to either transplantation or sVAD. Relative contraindications are similar to those for VAD as stated above.

To date, there have been no randomised trials assessing ECLS efficacy in hemodynamic support but observational studies exhibit promising results.

Two studies showed a benefit of ECLS performed in cardiac arrest [81, 82]. Short-term and 6-month survival rate were significantly increased in 59 and 85 patients under ECLS-CPR as compared with conventional CPR. Another study evaluated the outcomes of 81 patients who benefited from ECLS in severe refractory cardiogenic shock with long-term survival rates of 36% [77]. In comparison to biventricular assist devices, ECLS was as effective in recovery of fulminant myocarditis yet with faster renal and hepatic recovery [83].

Newer, minimised ECLS systems such as the ELS-System and Cardiohelp (both from MAQUET Cardiopulmonary AG, Germany) have been developed allowing rapid insertion and facilitated interhospital transport [84]. One case report showed safe application of Cardiohelp in 6 patients. Interhospital transport was done by car or helicopter and survival rate was 100% [85].

6. Future Devices

Another promising device not commercially available is the Reitan Catheter Pump (RCP; Kiwimed Ltd.). It consists of a catheter-mounted pump-head with a foldable propeller and surrounding cage. Positioned in the descending aorta, the pump creates a pressure gradient, reducing afterload and enhancing organ perfusion. One study confirmed its safety in 11 high-risk PCI patients [86]. Benefits on hemodynamic parameters especially cardiac output have not been shown in humans.

7. Conclusion

Acute heart failure and cardiogenic shock, regardless the cause, still have a dreadful outcome. Current management includes use of inotropic support and/or IABP. In the past decade, pVAD and ECLS have completed this armamentarium with which one can tackle these conditions. A true technological advance, proven to restore and maintain perfusion pressures. Although better hemodynamic parameters are interesting, improved clinical outcome has yet to be demonstrated. Ultimately, complications arising from insertion and costs further broaden the debate. In this sense, pVADs and ECLS are no plot devices, and the seemingly inextricable problem of acute heart failure is not likely to be solved with a sole object.

References

[1] M. Cohen, P. Urban, J. T. Christenson et al., “Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark® Registry,” European Heart Journal, vol. 24, no. 19, pp. 1763–1770, 2003.

[2] K. D. Sjauw, A. E. Engström, M. M. Vis et al., “A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?” European Heart Journal, vol. 30, no. 4, pp. 459–468, 2009.

[3] J. P. S. Henriques, M. Remmelink, J. J. Baan et al., “Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5,” American Journal of Cardiology, vol. 97, no. 7, pp. 990–992, 2006.
[4] H. Thiele, B. Lauer, R. Hambrecht, E. Boudriot, H. A. Cohen, and G. Schuler, "Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance," *Circulation*, vol. 104, no. 24, pp. 2917–2922, 2001.

[5] S. Cook, M. Togni, P. Wenaeser et al., "Interest of percutaneous assist devices for patients with cardiogenic shock," in *Proceedings of the 15th Congress of the International Society for Rotary Blood Pumps (ISRBP ’07)*, November 2007.

[6] K. Lam, K. D. Sjauw, J. van der Meulen et al., "A combined surgical and percutaneous approach through the axillary artery to introduce the Impella LP5.0 for short-term circulatory support," *International Journal of Cardiology*, vol. 134, no. 2, pp. 277–279, 2009.

[7] T. Sassard, A. Scalabre, E. Bonnefoy, I. Sanchez, F. Farhat, and O. Jegaden, "The right axillary artery approach for the Impella Recover LP 5.0 microaxial pump," *Annals of Thoracic Surgery*, vol. 85, no. 4, pp. 1468–1470, 2008.

[8] M. P. Reilly, S. E. Wiegers, A. J. Cucchiara et al., "Frequency, risk factors, and clinical outcomes of left ventricular assist device-associated ventricular thrombus," *American Journal of Cardiology*, vol. 86, no. 10, pp. 1156–1159, 2000.

[9] J. S. Forrester, G. Diamond, K. Chatterjee, and H. J. Swan, "Medical therapy of acute myocardial infarction by application of hemodynamic subsets," *New England Journal of Medicine*, vol. 295, no. 24, pp. 1356–1362, 1976.

[10] J. S. Hochman, "Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm," *Circulation*, vol. 107, no. 24, pp. 2998–3002, 2003.

[11] P. Urban, J. C. Stauffer, D. Bleed et al., "A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH," *European Heart Journal*, vol. 20, no. 14, pp. 1030–1038, 1999.

[12] S. Unosawa, M. Hata, A. Sezai et al., "Successful management of fulminant myocarditis with left ventricular assist device: report of a severe case," *Annals of Thoracic and Cardiovascular Surgery*, vol. 16, no. 1, pp. 48–51, 2010.

[13] A. Gupta, S. Allaqaband, and T. Bajwa, "Combined use of impella device and intra-aortic balloon pump to improve survival in a patient in profound cardiogenic shock post cardiac arrest," *Catheterization and Cardiovascular Interventions*, vol. 74, no. 6, pp. 975–976, 2009.

[14] V. Rajagopal, G. Stehr, C. I. Wilmer, and N. Y. Raval, "A novel percutaneous mechanical biventricular bridge to recovery in severe cardiac allograft rejection," *Journal of Heart and Lung Transplantation*, vol. 29, no. 1, pp. 93–95, 2010.

[15] H. Thiele, P. Sick, E. Boudriot et al., "Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock," *European Heart Journal*, vol. 26, no. 13, pp. 1276–1283, 2005.

[16] B. Meyns, J. Dens, P. Sergeant, P. Herijgers, W. Daenen, and W. Flameng, "Initial experiences with the impella device in patients with cardiogenic shock. Impella support for cardiogenic shock," *Thoracic and Cardiovascular Surgeon*, vol. 51, no. 6, pp. 312–317, 2003.

[17] J. M. Chen, J. J. Derose, J. P. Slater et al., "Improved survival rates support left ventricular assist device implantation early after myocardial infarction," *Journal of the American College of Cardiology*, vol. 33, no. 7, pp. 1903–1908, 1999.

[18] J. W. R. Entwistle, P. B. Bolno, E. Holmes, and L. E. Samuels, "Improved survival with ventricular assist device support in cardiogenic shock after myocardial infarction," *Heart Surgery Forum*, vol. 6, no. 5, pp. 316–319, 2003.

[19] D. Burkhoff, H. Cohen, C. Brunckhorst, and W. W. O’Neill, "A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intra-aortic balloon pumping for treatment of cardiogenic shock," *American Heart Journal*, vol. 152, no. 3, pp. 469.e1–469.e8, 2006.

[20] M. Seyfart, D. Sibbing, I. Bauer et al., "A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction," *Journal of the American College of Cardiology*, vol. 52, no. 19, pp. 1584–1588, 2008.

[21] B. Kar, I. D. Gregorici, S. S. Basra, G. M. Idelchik, and P. Loyalka, "The percutaneous ventricular assist device in severe refractory cardiogenic shock," *Journal of the American College of Cardiology*, vol. 51, no. 6, pp. 688–696, 2011.

[22] A. Lauten, A. E. Engström, C. Jung, K. Empen, P. Erne, S. Cook et al., "Percutaneous left ventricular support with the impella 2.5 in cardiogenic shock—results of the impella EUROSHOCK-registry," In press.

[23] J. M. Cheng, C. A. den Uil, S. E. Hoeks et al., "Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials," *European Heart Journal*, vol. 30, no. 17, pp. 2102–2108, 2009.

[24] S. Cook and S. Windecker, "Percutaneous ventricular assist devices for cardiogenic shock," *Current Heart Failure Reports*, vol. 5, no. 3, pp. 163–169, 2008.

[25] D. Chandra, B. Kar, G. Idelchik et al., "Usefulness of percutaneous left ventricular assist device as a bridge to recovery from myocarditis," *American Journal of Cardiology*, vol. 99, no. 12, pp. 1755–1756, 2007.

[26] I. D. Gregorici, L. P. Jacob, S. La Francesca et al., "The TandemHeart as a bridge to a long-term axial-flow left ventricular assist device," *Texas Heart Institute Journal*, vol. 35, no. 2, pp. 125–129, 2008.

[27] W. T. Brinkman, J. E. Rosenthal, E. Eichhorn et al., "Role of a percutaneous ventricular assist device in decision making for a cardiac transplant program," *Annals of Thoracic Surgery*, vol. 88, no. 5, pp. 1462–1466, 2009.

[28] W. Tayara, R. C. Starling, M. H. Yamani, O. Wazni, F. Lubran, and N. Smedira, "Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment," *Journal of Heart and Lung Transplantation*, vol. 25, no. 5, pp. 504–509, 2006.

[29] G. L. Zumbo, W. R. Kitchens, and G. Shearer, "Mechanical assistance for cardiogenic shock following cardiac surgery, myocardial infarction, and cardiac transplantation," *Annals of Thoracic Surgery*, vol. 44, no. 1, pp. 11–13, 1987.

[30] H. Noda, H. Takano, Y. Taenaka et al., "Treatment of acute myocardial infarction with cardiogenic shock using left ventricular assist device," *International Journal of Artificial Organs*, vol. 12, no. 3, pp. 175–179, 1989.

[31] J. D. Farrar, J. H. Lawson, P. Litwak, and G. Cederwall, "Thoratec VAD system as a bridge to heart transplantation," *Journal of Heart Transplantation*, vol. 9, no. 4, pp. 415–423, 1990.

[32] O. H. Frazier, E. A. Rose, Q. Macmanus et al., "Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device," *Circulation*, vol. 97, no. 1, pp. 1–10, 1998.
assist device,” *Annals of Thoracic Surgery*, vol. 53, no. 6, pp. 1080–1090, 1992.

[33] A. Moritz and E. Wolner, “Circulatory support with shock due to acute myocardial infarction,” *Annals of Thoracic Surgery*, vol. 55, no. 1, pp. 238–244, 1993.

[34] R. Körfer, A. El-Banayosy, H. Posival et al., “Mechanical circulatory support: the Bad Oeynhausen experience,” *Annals of Thoracic Surgery*, vol. 59, supplement 1, pp. S56–S63, 1995.

[35] W. J. Keon and D. B. Olsen, “Mechanical circulatory support as a bridge to transplantation: past, present and future,” *Canadian Journal of Cardiology*, vol. 12, no. 10, pp. 1017–1030, 1996.

[36] D. Y. Loisance, F. Pouillart, C. Benvenuti et al., “Mechanical bridge to transplantation: when is too early? When is too late?” *Annals of Thoracic Surgery*, vol. 61, no. 1, pp. 388–390, 1996.

[37] B. G. Leshnower, T. G. Gleason, M. L. O’Hara et al., “Safety and efficacy of left ventricular assist device support in postmyocardial infarction cardiogenic shock,” *Annals of Thoracic Surgery*, vol. 81, no. 4, pp. 1365–1371, 2006.

[38] W. Merhi, S. R. Dixon, W. W. O’Neill, G. S. Hanzel, and P. A. McCullough, “Percutaneous left ventricular assist device in acute myocardial infarction and cardiogenic shock,” *Reviews in Cardiovascular Medicine*, vol. 6, no. 2, pp. 118–123, 2005.

[39] G. M. Idelchik, P. Loyalka, and B. Kar, “Percutaneous ventricular assist device placement during active cardiopulmonary resuscitation for severe refractory cardiogenic shock after acute myocardial infarction,” *Texas Heart Institute Journal*, vol. 34, no. 2, pp. 204–208, 2007.

[40] F. Patané, E. Zingarelli, F. Sansone, and M. Rinaldi, “Acute ventricular septal defect treated with an Impella Recovery as a ‘bridge therapy’ to heart transplantation,” *Interactive Cardiovascular and Thoracic Surgery*, vol. 6, no. 6, pp. 818–819, 2007.

[41] I. D. Gregoric, M. C. Bieniarz, H. Arora, O. H. Frazier, B. Kar, and P. Loyalka, “Percutaneous ventricular assist device support: in a patient with a postinfarction ventricular septal defect,” *Texas Heart Institute Journal*, vol. 35, no. 1, pp. 46–49, 2008.

[42] B. A. Bruckner, L. P. Jacob, I. D. Gregoric et al., “Clinical experience with the TandemHeart percutaneous ventricular assist device as a bridge to cardiac transplantation,” *Texas Heart Institute Journal*, vol. 35, no. 4, pp. 447–450, 2008.

[43] G. M. Idelchik, L. Simpson, A. B. Civitello et al., “Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation,” *Journal of Heart and Lung Transplantation*, vol. 27, no. 1, pp. 106–111, 2008.

[44] P. Vranckx, D. P. Foley, P. J. De Feijter, J. Vos, F. Smits, and P. W. Serruys, “Clinical introduction of the TandemHeart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention,” *International Journal of Cardiovascular Interventions*, vol. 5, no. 1, pp. 35–39, 2003.

[45] J. Aragon, M. S. Lee, S. Kar, and R. R. Makkar, “Percutaneous left ventricular assist device: ‘TandemHeart’ for high-risk coronary intervention,” *Catheterization and Cardiovascular Interventions*, vol. 65, no. 3, pp. 346–352, 2005.

[46] C. Giombolini, S. Notaristefano, S. Santucci et al., “Percutaneous left ventricular assist device, TandemHeart™ for high-risk percutaneous coronary revascularization. A single centre experience,” *Acute Cardiac Care*, vol. 8, no. 1, pp. 35–40, 2006.

[47] B. Kar, L. E. Adkins, A. B. Civitello et al., “Clinical experience with the TandemHeart® percutaneous ventricular assist device,” *Texas Heart Institute Journal*, vol. 33, no. 2, pp. 111–115, 2006.

[48] B. Kar, M. Forrester, C. Gemmato et al., “Use of the TandemHeart percutaneous ventricular assist device to support patients undergoing high-risk percutaneous coronary intervention,” *Journal of Invasive Cardiology*, vol. 18, no. 3, pp. 93–96, 2006.

[49] P. Vranckx, E. Meliga, P. P. De Jaegere, M. Van den Ent, E. S. Regar, and P. W. Serruys, “The TandemHeart, percutaneous transapical left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience,” *EuroIntervention*, vol. 4, no. 3, pp. 331–337, 2008.

[50] S. Rajdev, P. Krishnan, A. Irani et al., “Clinical application of prophylactic percutaneous left ventricular assist device (TandemHeart®) in high-risk percutaneous coronary intervention using an arterial preclosure technique: single-center experience,” *Journal of Invasive Cardiology*, vol. 20, no. 2, pp. 67–72, 2008.

[51] W. Al-Husami, F. Yturralde, G. Mohanty et al., “Single-center experience with the TandemHeart percutaneous ventricular assist device to support patients undergoing high-risk percutaneous coronary intervention,” *Journal of Invasive Cardiology*, vol. 20, no. 6, pp. 319–322, 2008.

[52] P. Vranckx, C. J. Schultz, M. Valgimigli et al., “Assisted circulation using the TandemHeart® during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG,” *Catheterization and Cardiovascular Interventions*, vol. 74, no. 2, pp. 302–310, 2009.

[53] S. Cook, M. Togni, P. Wenaweser et al., “Clinical characteristics and follow up of patients needing implantation of percutaneous assist device (pVAD) for high risk percutaneous coronary intervention (PCI),” in *Proceedings of the 15th Congress of the International Society for Rotary Blood Pumps (ISRBP ’07)*, November 2007.

[54] G. Gimelli and M. R. Wolff, “Hemodynamically supported percutaneous coronary revascularization improves left ventricular function in patients with ischemic dilated cardiomyopathy at very high risk for surgery: a single-center experience,” *Journal of Invasive Cardiology*, vol. 20, no. 12, pp. 642–646, 2008.

[55] M. Valgimigli, P. Steendijk, P. W. Serruys et al., “Use of Impella Recover® LP 2.5 left ventricular assist device during high-risk percutaneous coronary interventions; clinical, haemodynamic and biochemical findings,” *EuroIntervention*, vol. 2, pp. 91–100, 2006.

[56] J. L. Thomas, H. Al-Ameri, C. Economides et al., “Use of a percutaneous left ventricular assist device for high-risk cardiac interventions and cardiogenic shock,” *Journal of Invasive Cardiology*, vol. 22, no. 8, pp. 360–364, 2010.

[57] J. P. S. Henriques, M. Remmelink, J. J. Bana et al., “Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5,” *American Journal of Cardiology*, vol. 97, no. 7, pp. 980–982, 2006.

[58] M. Remmelink, K. D. Sjaauw, J. P. S. Henriques et al., “Effects of left ventricular unloading by Impella Recover LP 2.5 on coronary hemodynamics,” *Catheterization and Cardiovascular Interventions*, vol. 70, no. 4, pp. 532–537, 2007.

[59] F. Burzotta, L. Paloscia, C. Trani et al., “Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study,” *Journal of Cardiovascular Medicine*, vol. 9, no. 10, pp. 1004–1010, 2008.
[60] S. Vecchio, T. Chechi, G. Giuliani et al., “Use of Impella Recover 2.5 left ventricular assist device in patients with cardiogenic shock or undergoing high-risk percutaneous coronary intervention procedures: experience of a high-volume center,” Minerva Cardioangiologica, vol. 56, no. 4, pp. 391–399, 2008.

[61] J. Eichhöfer, M. Osten, E. Horlick, and V. Džavík, “First Canadian experience with high-risk percutaneous coronary intervention with assistance of a percutaneously deployed left ventricular assist device,” Canadian Journal of Cardiology, vol. 24, no. 11, pp. e82–e85, 2008.

[62] S. R. Dixon, J. P. S. Henriques, L. Mauri et al., “A Prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I trial): initial U.S. Experience,” Journal of the American College of Cardiology, vol. 2, no. 2, pp. 91–96, 2009.

[63] K. E. Iliodromitis, P. Kahlert, B. Plicht et al., “High-risk PCI in acute coronary syndromes with Impella LP 2.5 device support,” International Journal of Cardiology. In press.

[64] S. Thomopoulou, A. Manginas, and D. V. Cokkinos, “Initial experience with the Impella Recover LP 2.5 micro-axial pump in patients undergoing high-risk coronary angioplasty,” Hellenic Journal of Cardiology, vol. 49, no. 6, pp. 382–387, 2008.

[65] M. Remmelink, K. D. Sjauw, J. P. Henriques et al., “Effects of mechanical left ventricular unloading by impella on left ventricular dynamics in high-risk and primary percutaneous coronary intervention patients,” Catheterization and Cardiovascular Interventions, vol. 75, no. 2, pp. 187–194, 2010.

[66] P. Vranckx, C. J. Schultz, M. Valgimigli et al., “Assisted circulation using the TandemHeart® during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG,” Catheterization and Cardiovascular Interventions, vol. 74, no. 2, pp. 302–310, 2009.

[67] J. L. Ferreiro, J. A. Gómez-Hospital, Á. R. Cequier et al., “Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention,” International Journal of Cardiology, vol. 145, no. 2, pp. 235–237, 2010.

[68] K. D. Sjauw, T. Konorza, R. Erbel et al., “Supported high-risk percutaneous coronary intervention with impella 2.5 device the europella registry,” Journal of the American College of Cardiology, vol. 54, no. 23, pp. 2430–2434, 2009.

[69] “PROTECT II: a prospective, multi-center, randomized controlled trial of the Impella Recover LP 2.5 system versus intra aortic balloon pump (IABP) in patients undergoing non emergent high risk PCI,” Abiomed Inc.

[70] P. A. Friedman, T. M. Munger, N. Torres, and C. Rihal, “Percutaneous endocardial and epicardial ablation of hypertensive ventricular tachycardia with percutaneous left ventricular assist in the electrophysiology laboratory,” Journal of Cardiovascular Electrophysiology, vol. 18, no. 1, pp. 106–109, 2007.

[71] H. Abuissa, J. Roshan, B. Lim, and S. J. Asvatham, “Use of the Impella™ microaxial blood pump for ablation of hemodynamically unstable ventricular tachycardia,” Journal of Cardiovascular Electrophysiology, vol. 21, no. 4, pp. 458–461, 2010.

[72] S. B. Fishberger, J. D. Asnes, N. L. Rollinson, and M. W. Cleman, “Percutaneous right ventricular support during catheter ablation of intra-atrial reentrant tachycardia in an adult with a mustard baffle—a novel use of the Impella device,” Journal of Interventional Cardiac Electrophysiology, vol. 29, no. 1, pp. 69–72, 2010.

[73] M. W. Tempelhof, L. Klein, W. G. Cotts et al., “Clinical experience and patient outcomes associated with the TandemHeart percutaneous transeptal assist device among a heterogeneous patient population,” ASAIO Journal, vol. 57, no. 4, pp. 254–261, 2011.

[74] G. M. Giesler, J. S. Gomez, G. Letsou, M. Vooletich, and R. W. Smalling, “Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction,” Catheterization and Cardiovascular Interventions, vol. 68, no. 2, pp. 78–82, 2006.

[75] A. D. Atiemo, J. V. Conte, and A. W. Heldman, “Resuscitation and recovery from acute right ventricular failure using a percutaneous right ventricular assist device,” Catheterization and Cardiovascular Interventions, vol. 68, no. 1, pp. 78–82, 2006.

[76] B. D. Atwater, L. M. Nee, and G. Gimelli, “Long-term survival using intra-aortic balloon pump and percutaneous right ventricular assist device for biventricular mechanical support of cardiogenic shock,” Journal of Invasive Cardiology, vol. 20, no. 7, pp. E205–E207, 2008.

[77] A. Combes, P. Leprince, C. E. Luyt et al., “Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock,” Critical Care Medicine, vol. 36, no. 5, pp. 1404–1411, 2008.

[78] J. G. Younger, R. J. Schreiner, F. Swaniker, R. B. Hirschl, R. A. Chapman, and R. H. Bartlett, “Extracorporeal resuscitation of cardiac arrest,” Academic Emergency Medicine, vol. 6, no. 7, pp. 700–707, 1999.

[79] A. J. Rastan, A. Dege, M. Mohr et al., “Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock,” Journal of Thoracic and Cardiovascular Surgery, vol. 139, no. 2, pp. 302–311, 2010.

[80] F. D. Pagani, K. D. Aaronson, F. Swaniker, and R. H. Bartlett, “The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device,” Annals of Thoracic Surgery, vol. 71, no. 3, supplement 1, pp. S77–S81, 2001.

[81] T. G. Shin, J.-H. Choi, I. J. Jo et al., “Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: a comparison with conventional cardiopulmonary resuscitation,” Critical Care Medicine, vol. 39, no. 1, pp. 1–7, 2011.

[82] Y. S. Chen, J. W. Lin, H. Y. Yu et al., “Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis,” The Lancet, vol. 372, no. 9638, pp. 554–561, 2008.

[83] O. N. Pages, S. Aubert, A. Combes et al., “Paracorporeal pulsatile biventricular assist device versus extracorporeal membrane oxygenation-extracorporeal life support in adult fulminant myocarditis,” Journal of Thoracic and Cardiovascular Surgery, vol. 137, no. 1, pp. 194–197, 2009.

[84] M. Arlt, A. Philipp, S. Voelkel et al., “Hand-held minimised extracorporeal membrane oxygenation: a new bridge to recovery in patients with out-of-centre cardiogenic shock,” European Journal of Cardio-Thoracic Surgery. In press.

[85] A. Philipp, M. Arlt, M. Amann et al., “First experience with the ultra compact mobile extracorporeal membrane oxygenation system cardiolife in interhospital transport,” Interactive Cardiovascular and Thoracic Surgery, vol. 12, no. 6, pp. 978–981, 2011.
[86] E. J. Smith, O. Reitan, T. Keeble, K. Dixon, and M. T. Rothman, "A first-in-man study of the reitan catheter pump for circulatory support in patients undergoing high-risk percutaneous coronary intervention," Catheterization and Cardiovascular Interventions, vol. 73, no. 7, pp. 859–865, 2009.